Analysts’ Weekly Ratings Changes for Arcutis Biotherapeutics (ARQT)

A number of firms have modified their ratings and price targets on shares of Arcutis Biotherapeutics (NASDAQ: ARQT) recently:

• 10/19/2026 – Arcutis Biotherapeutics had its price target raised by Guggenheim from $38.00 to $44.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Arcutis Biotherapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $48.00 price target on the stock.
• 10/14/2026 – Arcutis Biotherapeutics was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 10/10/2026 – Arcutis Biotherapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/8/2026 – Arcutis Biotherapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $39.00 price target on the stock.
• 9/24/2026 – Arcutis Biotherapeutics was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/8/2026 – Arcutis Biotherapeutics was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.

Insider Activity at Arcutis Biotherapeutics

In other news, insider Todd Watanabe sold 4,375 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the transaction, the insider owned 717,203 shares in the company, valued at approximately $18,733,342.36. This trade represents a 0.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Terrie Curran sold 38,200 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $25.03, for a total value of $956,146.00. Following the transaction, the director owned 23,526 shares in the company, valued at approximately $588,855.78. This trade represents a 61.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 83,953 shares of company stock worth $2,143,291. 9.40% of the stock is currently owned by company insiders.

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.